{"doi":"10.1002/prot.70068","title":"Assessment of Protein Complex Predictions in <scp>CASP16</scp> : Are We Making Progress?","abstract":"The assessment of oligomer targets in the Critical Assessment of Structure Prediction Round 16 (CASP16) suggests that complex structure prediction remains an unsolved challenge. Even the leading groups can only predict slightly more than half of the targets to high accuracy. Most CASP16 groups relied on AlphaFold-Multimer (AFM) or AlphaFold3 (AF3) as their core modeling engines. By optimizing input MSAs, refining modeling constructs (using partial rather than full sequences), and employing massive model sampling and selection, top-performing groups were able to significantly outperform the default AFM/AF3 predictions. CASP16 also introduced two additional challenges: Phase 0, which required predictions without stoichiometry information, and Phase 2, which provided participants with thousands of models generated by MassiveFold (MF) to enable large-scale sampling for resource-limited groups. Across all phases, the MULTICOM series and Kiharalab emerged as top performers based on the quality of their best models. However, these groups did not have a strong advantage in model ranking, and thus their lead over other teams, such as Yang-Multimer and kozakovvajda, was less pronounced when evaluating only the first submitted models. Compared to CASP15, CASP16 showed moderate overall improvement, likely driven by the release of AF3 and the extensive model sampling employed by top groups. Several notable trends highlight frontiers for future development. First, the kozakovvajda group significantly outperformed others on antibody-antigen targets, achieving over a 60% success rate without relying on AFM or AF3 as their primary modeling framework, suggesting that alternative approaches may offer promising solutions for these difficult targets. Second, model ranking and selection continue to be major bottlenecks. The PEZYFoldings group demonstrated a notable advantage in selecting their best models as first models, suggesting that their pipeline for model ranking may offer important insights for the field. Finally, the Phase 0 experiment indicated moderate success in stoichiometry prediction; however, stoichiometry prediction remains challenging for high-order assemblies and targets that differ from available homologous templates. Overall, CASP16 demonstrated steady progress in multimer prediction while emphasizing the need for more effective model ranking strategies, improved stoichiometry prediction, and new modeling methods that extend beyond the current AF-based paradigm.","journal":"Proteins Structure Function and Bioinformatics","year":2025,"id":514580,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":8,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9535,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1169922,"name":"Rongqing Yuan","orcid":"0000-0001-5917-4505","position":1,"is_corresponding":false},{"id":560413,"name":"Andriy Kryshtafovych","orcid":"0000-0001-5066-7178","position":2,"is_corresponding":false},{"id":217617,"name":"Jimin Pei","orcid":"0000-0002-3505-9665","position":3,"is_corresponding":false},{"id":232524,"name":"Rachael C. Kretsch","orcid":"0000-0002-6935-518X","position":4,"is_corresponding":false},{"id":288162,"name":"R. Dustin Schaeffer","orcid":"0000-0001-6502-1425","position":5,"is_corresponding":false},{"id":1377268,"name":"Jian Zhou","orcid":"0000-0001-8290-3104","position":6,"is_corresponding":false},{"id":235783,"name":"Rhiju Das","orcid":"0000-0001-7497-0972","position":7,"is_corresponding":false},{"id":396818,"name":"Nick V. Grishin","orcid":"0000-0003-4108-1153","position":8,"is_corresponding":false},{"id":572645,"name":"Qian Cong","orcid":"0000-0002-8909-0414","position":9,"is_corresponding":false},{"id":445354,"name":"Jing Zhang","orcid":"0000-0003-4190-3065","position":0,"is_corresponding":true}],"reference_count":51,"raw_metadata":null,"created_at":"2026-07-19T02:48:29.165853Z","pmid":"41170922","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}